Clinical trials: Migraine, Acute
Migraine
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine
This is a double-blind, randomized, multicenter, outpatient evaluation of the safety and efficacy of elismetrep as compared to placebo in the acute treatment of migraine.
- Trial name
- NCT06848075
- Testing
- Elismetrep (K-304) 2 mg, Elismetrep (K-304) 5 mg, Elismetrep (K-304) 10 mg
- Where
- 66 sites in United States
- Volunteers
- 431 people
- Sponsor
- TriGemX Bio, Inc.
Migraine Headache
Study in Participants With Acute Migraines Headaches
This is a Phase 2, multicenter, randomized, double-blind, placebo and active comparator-controlled study of LY2590443 in approximately 200 participants with migraines.
- Trial name
- NCT00804973
- Testing
- LY2590443, Sumatriptan
- Where
- 19 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Acute Migraine
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
This is a prospective randomized, double-blind, placebo-controlled study in participants with disabling migraine (Migraine Disability Assessment (MIDAS) score ≥ 11).
- Trial name
- SAMURAI (NCT02439320)
- Testing
- Lasmiditan 100 mg, Lasmiditan 200 mg
- Where
- 92 sites in United States
- Volunteers
- 2,231 people
- Sponsor
- Eli Lilly and Company
Migraine, Migraine With Aura
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess STS101 in the Acute Treatment of Migraine
Study STS101-007 is a randomized, double-blind, parallel group, placebo-controlled, multicenter study to evaluate the efficacy, safety, and tolerability of single doses of STS101 (dihydroergotamine nasal powder) in the acute…
- Conditions
- Migraine, Migraine With Aura, Migraine Without Aura
- Trial name
- SUMMIT (NCT04940390)
- Testing
- Dihydroergotamine
- Where
- 127 sites in United States
- Volunteers
- 1,591 people
- Sponsor
- Satsuma Pharmaceuticals, Inc.
Migraine Headache
Treatment of Multiple Attacks of Acute Migraine (0462-025)
A study to evaluate rizatriptan for the treatment of multiple attacks of acute migraine compared to placebo.
- Trial name
- NCT00899379
- Testing
- rizatriptan benzoate
- Volunteers
- 473 people
- Sponsor
- Organon and Co
Migraine
Pharmacokinetics & Safety of Cambia® in Migraine With or Without Aura in 12-17 Year Olds
Study Objectives: 1. The primary objective is to characterize the pharmacokinetics of a single oral administration of 50 mg Cambia in pediatric subjects, ages 12-17 years with a diagnosis of episodic migraine with or without…
- Trial name
- NCT02287376
- Testing
- Diclofenac Potassium for Oral Solution
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Depomed
Acute Migraine
Safety and Efficacy of Nerivio™ for the Acute Treatment of Migraine in Adolescents
Nerivio™ is an FDA-authorized remote electrical neuromodulation (REN) device for the acute treatment of migraine with or without aura in patients 18 years old or above who do not have chronic migraine.
- Trial name
- NCT04089761
- Testing
- Nerivio
- Where
- 12 sites in United States
- Volunteers
- 60 people
- Sponsor
- Theranica
Acute Migraine
A Study to Learn About the Long-term Safety of Rimegepant for the Acute Treatment of Migraine in Chinese Participants
This trial is to evaluate the long-term safety and tolerability of Rimegepant 75mg ODT in Chinese subjects with migraine
- Trial name
- NCT05371652
- Testing
- Rimegepant 75mg Orally Disintegrating Tablets (ODT)
- Where
- 26 sites in China
- Volunteers
- 241 people
- Sponsor
- Pfizer
Acute Migraine
A Proof of Concept Study of the Efficacy and Safety of Oral LAT8881 in Acute Migraine
This is a randomised, placebo controlled, double blind, crossover proof of concept study to investigate the efficacy and safety of oral LAT8881 in acute migraine, with or without aura.
- Trial name
- NCT04153409
- Testing
- LAT8881
- Where
- 3 sites in Australia
- Volunteers
- 21 people
- Sponsor
- Lateral Pharma Pty Ltd
Migraine
MK3207 for Treatment of Acute Migraines (3207-005)
The purpose of the study is to demonstrate the effectiveness and appropriate dosage level of MK3207 in the treatment of acute migraine.
- Trial name
- NCT00712725
- Testing
- MK3207- 2.5 mg, MK3207- 5 mg, MK3207- 10 mg
- Volunteers
- 676 people
- Sponsor
- Merck Sharp & Dohme LLC
Migraine
A Study to Evaluate the Long-Term Safety of M207 in the Acute Treatment of Migraine
This is an open-label, twelve-month safety study. There is a screening period followed by a run-in period to record migraine activity.
- Trial name
- ADAM (NCT03282227)
- Testing
- M207 Microneedle System
- Where
- 31 sites in United States
- Volunteers
- 342 people
- Sponsor
- Zosano Pharma Corporation
Migraine, Migraine With Aura
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate STS101 in the Acute Treatment of Migraine
Study STS101-002 is a randomized, double-blind, parallel group, placebo-controlled, multicenter study to evaluate the efficacy, safety, and tolerability of single doses of STS101 (dihydroergotamine nasal powder) in the acute…
- Conditions
- Migraine, Migraine With Aura, Migraine Without Aura
- Trial name
- EMERGE (NCT03901482)
- Testing
- Dihydroergotamine
- Where
- 117 sites in United States
- Volunteers
- 1,201 people
- Sponsor
- Satsuma Pharmaceuticals, Inc.
Migraine
Study to Test Rizatriptan in the Early Treatment of Acute Migraine (0462-081)
The purpose of this study is to test the effectiveness of rizatriptan benzoate in the early treatment of an acute migraine attack.
- Trial name
- NCT00516737
- Testing
- Comparator: rizatriptan benzoate
- Volunteers
- 207 people
- Sponsor
- Organon and Co
Migraine
A Phase III Trial of e-TNS for the Acute Treatment of Migraine
The main objective of this study is to have Phase III evidences of the efficacy of the Cefaly® Abortive Program device used at home for 2 hours to treat a migraine attack.
- Trial name
- TEAM (NCT03465904)
- Testing
- Verum Cefaly® Abortive Program device
- Where
- 10 sites in United States
- Volunteers
- 607 people
- Sponsor
- Cefaly Technology
Migraine
Comparison of Patient-reported Outcomes for Rimegepant and Triptans in the 2023 US National Health and Wellness Survey
This is a cross-sectional study using the cross-sectional 2023 National Health and Wellness Survey (NHWS) data from the US, with a large and nationally representative population (N=75,007).
- Trial name
- NCT06680206
- Testing
- Rimegepant, Triptans
- Where
- United States
- Volunteers
- 1,395 people
- Sponsor
- Pfizer
Migraine Without Aura, Migraine With Aura
Evaluation of a Novel Device for Treatment of Migraine Headache
Migraine is a common neurologic with attacks of headache and associated symptoms such as nausea, vomiting, phono and photophobia. Migraine can lead to substantial functional impairment.
- Trial name
- NCT03361423
- Testing
- Nerivio Migra-1 active device
- Where
- 12 sites in United States, Israel
- Volunteers
- 296 people
- Sponsor
- Theranica
Acute Migraine
Safety and Efficacy Trial of BHV3000 (Rimegepant) 75 mg for the Acute Treatment of Migraine
This trial is to determine whether BHV3000 (rimegepant) 75mg is safe and effictive as a treatment for acute migraine in Chinese and Korean patients
- Trial name
- NCT04574362
- Testing
- Rimegepant
- Where
- 90 sites in China, South Korea
- Volunteers
- 1,648 people
- Sponsor
- Pfizer
Migraine
A Study to Evaluate the Efficacy and Safety of Eptinezumab Administered Intravenously in Participants Experiencing Acute Attack of Migraine
The purpose of this study is to evaluate the efficacy and safety of eptinezumab administered intravenously in participants experiencing an acute attack of migraine.
- Trial name
- RELIEF (NCT04152083)
- Testing
- Eptinezumab
- Where
- 57 sites in United States, Georgia
- Volunteers
- 485 people
- Sponsor
- H. Lundbeck A/S
Migraine With or Without Aura, Migraine
Cooling to Alleviate Migraine #3
This is a prospective, double-blind, sham-controlled, randomized, decentralized trial. This study aims to assess the safety and efficacy of the Mi-Helper transnasal cooling device for acute treatment of migraine in an at home…
- Conditions
- Migraine With or Without Aura, Migraine, Migraine Headache
- Trial name
- CALM3 (NCT06874361)
- Testing
- Mi-Helper
- Where
- United States
- Volunteers
- 156 people
- Sponsor
- Mi-Helper, Inc.
Acute Migraine
Efficacy and Safety of Acetaminophen and Aspirin Versus Placebo in the Acute Treatment of Migraine
The purpose of the study is to evaluate the efficacy and safety of acetaminophen and aspirin versus placebo in the acute treatment of migraine
- Trial name
- NCT01973205
- Testing
- Acetaminophen 250 mg and Aspirin 250 mg
- Where
- 19 sites in United States
- Volunteers
- 900 people
- Sponsor
- Novartis